Table 2

Multiple regression parameter estimates and 95% CIs for model predictors based on observed hearing thresholds for the average of left and right ears

Frequency (Hz)
2505001,0002,0003,0004,0006,0008,000
n = 290n = 290n = 290n = 290n = 290n = 290n = 290n = 290
Intercept4.582 (1.84–7.33)3.987 (1.35–6.62)2.777 (0.49–5.07)2.593 (0.02–5.17)2.145 (−0.55–4.84)4.208 (1.10–7.31)2.745 (−0.72–6.21)4.106 (0.53–7.68)
Baseline0.641 (0.54–0.74)0.734 (0.65–0.82)0.867 (0.80–0.94)0.903 (0.85–0.96)0.946 (0.90–0.99)0.931 (0.89–0.97)0.889 (0.84–0.94)0.875 (0.83–0.92)
Age group 4 [70, 80) y3.229 (0.07–6.39)3.550 (0.40–6.70)2.383 (−0.31–5.08)5.258 (2.15–8.37)3.440 (0.12–6.76)2.658 (−1.18–6.49)5.127 (0.77–9.48)4.368 (−0.12–8.85)
Age group 3 [60, 70) y1.695 (−1.01–4.40)1.232 (−1.51–3.98)1.095 (−1.25–3.44)2.813 (0.15–5.48)3.307 (0.56–6.05)2.403 (−0.79–5.60)3.582 (0.03–7.14)3.768 (0.04–7.49)
Age group 2 [50, 60) y0.276 (−2.44–2.99)0.127 (−2.60–2.85)−0.150 (−2.49–2.19)1.119 (−1.53–3.77)1.094 (−1.64–3.83)0.319 (−2.84–3.47)2.198 (−1.28–5.67)2.653 (−0.96–6.27)
Age group 1 [40, 50) y
DFMO plus sulindac (n = 151)0.808 (−0.66–2.28)0.596 (−0.87–2.06)1.076 (−0.19–2.34)1.056 (−0.38–2.49)1.455 (−0.08–2.99)0.365 (−1.34–2.07)0.694 (−1.26–2.65)0.186 (−1.77–2.14)
Placebo (n = 139)

NOTE: Comparison reference groups were age group 1 [40, 50) y and placebo treatment group.